NCT_ID,Sponsor,Study_Name,Start_Date,End_Date,Current_Status,Facility,Lat,Lon,City,State,Zip,Country,Hover_City,Facility_dedupe,Dedupe_City
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,University of Alabama at Birmingham,33.52066,-86.80249,Birmingham,Alabama,35233,United States,"Birmingham, Alabama, United States",University of Alabama at Birmingham,"Birmingham, Alabama, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,"University of California, Irvine Medical Center",33.66946,-117.82311,Irvine,California,92868,United States,"Irvine, California, United States","University of California, Irvine Medical Center","Irvine, California, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Rady Children's Hospital,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,"UCSD, Rady Children's Hospital",32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Rady Children's Hospital - San Diego,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Rady Children's Hospital,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,32.71533,-117.15726,San Diego,California,32123,United States,"San Diego, California, United States",Ovid Therapeutics Investigative Site,"San Diego, California, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,"University of California, San Diego - Rady Children's Hospital",32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Rady Children's Hospital,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Rady Children's Hospital - San Diego,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,32.71533,-117.15726,San Diego,California,32123,United States,"San Diego, California, United States",Ovid Therapeutics Investigative Site,"San Diego, California, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Rady Children's Hospital San Diego,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,"Rady Children's Hospital, San Diego",32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT00348933,"University of California, San Diego",Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome,2006-07-03,2010-02,COMPLETED,Rady Children's Hospital San Diego,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT04103333,Biogen,A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome,2019-09-24,2022-01-02,COMPLETED,Rady Childrens Hospital,32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,32.71533,-117.15726,San Diego,California,32123,United States,"San Diego, California, United States",Ovid Therapeutics Investigative Site,"San Diego, California, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,"Rady Children's Hospital, San Diego",32.71533,-117.15726,San Diego,California,92123,United States,"San Diego, California, United States","University of California, San Diego - Rady Children's Hospital","San Diego, California, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,University of Florida College of Medicine,29.65163,-82.32483,Gainesville,Florida,32601,United States,"Gainesville, Florida, United States",University of Florida College of Medicine,"Gainesville, Florida, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,29.65163,-82.32483,Gainesville,Florida,,United States,"Gainesville, Florida, United States",Ovid Therapeutics Investigative Site,"Gainesville, Florida, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Kansas University Medical Center,39.11417,-94.62746,Kansas City,Kansas,66160,United States,"Kansas City, Kansas, United States",Kansas University Medical Center,"Kansas City, Kansas, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Children's Hospital Boston,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Clinical Trial Site,"Boston, Massachusetts, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Boston, Massachusetts, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT00829439,Boston Children's Hospital,A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome,2009-01-26,2010-06,COMPLETED,Children's Hospital Boston,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Boston, Massachusetts, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,Children's Hospital Boston,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT00348933,"University of California, San Diego",Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome,2006-07-03,2010-02,COMPLETED,Children's Hospital Boston,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT04103333,Biogen,A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome,2019-09-24,2022-01-02,COMPLETED,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Boston, Massachusetts, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Boston Children's Hospital,42.35843,-71.05977,Boston,Massachusetts,02115,United States,"Boston, Massachusetts, United States",Children's Hospital Boston,"Boston, Massachusetts, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Greenwood Genetic Center,34.1954,-82.16179,Greenwood,South Carolina,29646,United States,"Greenwood, South Carolina, United States",Greenwood Genetics Center,"Greenwood, South Carolina, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Greenwood Genetic Center,34.1954,-82.16179,Greenwood,South Carolina,29646,United States,"Greenwood, South Carolina, United States",Greenwood Genetics Center,"Greenwood, South Carolina, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,Greenwood Genetic Center,34.1954,-82.16179,Greenwood,South Carolina,29646,United States,"Greenwood, South Carolina, United States",Greenwood Genetics Center,"Greenwood, South Carolina, United States"
NCT00348933,"University of California, San Diego",Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome,2006-07-03,2010-02,COMPLETED,Greenwood Genetics Center,34.1954,-82.16179,Greenwood,South Carolina,,United States,"Greenwood, South Carolina, United States",Greenwood Genetics Center,"Greenwood, South Carolina, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,34.1954,-82.16179,Greenwood,South Carolina,,United States,"Greenwood, South Carolina, United States",Ovid Therapeutics Investigative Site,"Greenwood, South Carolina, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Vanderbilt University,36.16589,-86.78444,Nashville,Tennessee,37240,United States,"Nashville, Tennessee, United States",Vanderbilt University Medical Center,"Nashville, Tennessee, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Vanderbilt Children's Hospital,36.16589,-86.78444,Nashville,Tennessee,37232-9119,United States,"Nashville, Tennessee, United States",Monroe Carell Jr. Children's Hospital at Vanderbilt,"Nashville, Tennessee, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Ovid Therapeutics Investigative Site,"Nashville, Tennessee, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Vanderbilt University,36.16589,-86.78444,Nashville,Tennessee,37240,United States,"Nashville, Tennessee, United States",Vanderbilt University Medical Center,"Nashville, Tennessee, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Ovid Therapeutics Investigative Site,"Nashville, Tennessee, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Vanderbilt University Medical Center,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Vanderbilt University Medical Center,"Nashville, Tennessee, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,Vanderbilt University Medical Center,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Vanderbilt University Medical Center,"Nashville, Tennessee, United States"
NCT04103333,Biogen,A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome,2019-09-24,2022-01-02,COMPLETED,Vanderbilt University Medical Center,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Vanderbilt University Medical Center,"Nashville, Tennessee, United States"
NCT03109756,Ovid Therapeutics Inc.,A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome,2017-04-06,2017-11-28,COMPLETED,Ovid Therapeutics Investigative Site,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Ovid Therapeutics Investigative Site,"Nashville, Tennessee, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,36.16589,-86.78444,Nashville,Tennessee,37212,United States,"Nashville, Tennessee, United States",Ovid Therapeutics Investigative Site,"Nashville, Tennessee, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Monroe Carell Jr. Children's Hospital at Vanderbilt,36.16589,-86.78444,Nashville,Tennessee,37232,United States,"Nashville, Tennessee, United States",Monroe Carell Jr. Children's Hospital at Vanderbilt,"Nashville, Tennessee, United States"
NCT02670694,Baylor College of Medicine,"Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi",2015-11-06,2013-07,COMPLETED,Baylor College of Medicine,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Texas Children's Hospital,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Texas Children's Hospital,"Houston, Texas, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Red Oak Psychiatry Associates,29.76328,-95.36327,Houston,Texas,77090,United States,"Houston, Texas, United States",Red Oak Psychiatry Associates,"Houston, Texas, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Baylor College of Med; Texas Child Hosp; Pediactric Dept,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Baylor College of Medicine,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,Dr. Meltzer Clinic,29.76328,-95.36327,Houston,Texas,77054,United States,"Houston, Texas, United States",Dr. Meltzer Clinic,"Houston, Texas, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,Baylor College of Medicine,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT00348933,"University of California, San Diego",Efficacy of a Therapeutic Treatment Trial in Angelman Syndrome,2006-07-03,2010-02,COMPLETED,Baylor College of Medicine,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT00004351,Office of Rare Diseases (ORD),Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes,1999-10-18,unknown,COMPLETED,Baylor College of Medicine,29.76328,-95.36327,Houston,Texas,77030,United States,"Houston, Texas, United States",Baylor College of Med; Texas Child Hosp; Pediactric Dept,"Houston, Texas, United States"
NCT04863794,Hoffmann-La Roche,"A Non-Randomized, Open-Label, Adaptive, Single Center, Positron Emission Tomography (Pet) Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants",2021-04-26,2022-08-01,COMPLETED,Pra International Group B.V,53.21917,6.56667,Groningen,,9728 NZ,Netherlands,"Groningen, Netherlands",Pra International Group B.V,"Groningen, Netherlands"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,University Medical Center Groningen,53.21917,6.56667,Groningen,,,Netherlands,"Groningen, Netherlands",University Medical Center Groningen,"Groningen, Netherlands"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,34.05223,-118.24368,Los Angeles,California,90048,United States,"Los Angeles, California, United States",Clinical Trial Site,"Los Angeles, California, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,"University of California, Los Angeles (UCLA)",34.05223,-118.24368,Los Angeles,California,90095,United States,"Los Angeles, California, United States","University of California, Los Angeles (UCLA)","Los Angeles, California, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,UCLA Medical Center,34.05223,-118.24368,Los Angeles,California,90095,United States,"Los Angeles, California, United States",UCLA Medical Center,"Los Angeles, California, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,UCLA Neuropsychiatric Institute,34.05223,-118.24368,Los Angeles,California,90024,United States,"Los Angeles, California, United States",UCLA Neuropsychiatric Institute,"Los Angeles, California, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,37.77493,-122.41942,San Francisco,California,94143,United States,"San Francisco, California, United States",Clinical Trial Site,"San Francisco, California, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,"University of California, San Francisco",37.77493,-122.41942,San Francisco,California,94121,United States,"San Francisco, California, United States","University of California, San Francisco","San Francisco, California, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,"University of California, San Francisco",37.77493,-122.41942,San Francisco,California,94121,United States,"San Francisco, California, United States","University of California, San Francisco","San Francisco, California, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,39.73915,-104.9847,Denver,Colorado,80045,United States,"Denver, Colorado, United States",Clinical Trial Site,"Denver, Colorado, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,25.77427,-80.19366,Miami,Florida,33155,United States,"Miami, Florida, United States",Clinical Trial Site,"Miami, Florida, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Rare Disease Research,33.749,-84.38798,Atlanta,Georgia,30318,United States,"Atlanta, Georgia, United States","Rare Disease Research, LLC","Atlanta, Georgia, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,"Rare Disease Research, LLC",33.749,-84.38798,Atlanta,Georgia,30329,United States,"Atlanta, Georgia, United States","Rare Disease Research, LLC","Atlanta, Georgia, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Rare Disease Research,33.749,-84.38798,Atlanta,Georgia,30318,United States,"Atlanta, Georgia, United States","Rare Disease Research, LLC","Atlanta, Georgia, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,33.749,-84.38798,Atlanta,Georgia,30322,United States,"Atlanta, Georgia, United States",Ovid Therapeutics Investigative Site,"Atlanta, Georgia, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,33.749,-84.38798,Atlanta,Georgia,30322,United States,"Atlanta, Georgia, United States",Ovid Therapeutics Investigative Site,"Atlanta, Georgia, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Emory University School of Medicine,33.749,-84.38798,Atlanta,Georgia,30322,United States,"Atlanta, Georgia, United States",Emory University School of Medicine,"Atlanta, Georgia, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Rush University,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Rush Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Rush University Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Ovid Therapeutics Investigative Site,"Chicago, Illinois, United States"
NCT06139172,Rush University Medical Center,Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities,2023-11-14,2026-12,RECRUITING,Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Rush University Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Rush University Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Rush Medical Center,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Ovid Therapeutics Investigative Site,"Chicago, Illinois, United States"
NCT04103333,Biogen,A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome,2019-09-24,2022-01-02,COMPLETED,Rush Medical College,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Autism Assessment Research Treatment and Services (AARTS) Center at Rush University Medical Center,"Chicago, Illinois, United States"
NCT03109756,Ovid Therapeutics Inc.,A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome,2017-04-06,2017-11-28,COMPLETED,Ovid Therapeutics Investigative Site,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Ovid Therapeutics Investigative Site,"Chicago, Illinois, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Ovid Therapeutics Investigative Site,"Chicago, Illinois, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Rush University Children's Hospital,41.85003,-87.65005,Chicago,Illinois,60612,United States,"Chicago, Illinois, United States",Rush University Children's Hospital,"Chicago, Illinois, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Children's Mercy,39.09973,-94.57857,Kansas City,Missouri,64108,United States,"Kansas City, Missouri, United States",Children's Mercy,"Kansas City, Missouri, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,40.71427,-74.00597,New York,New York,10032,United States,"New York, New York, United States",Clinical Trial Site,"New York, New York, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Columbia University Medical Center,40.71427,-74.00597,New York,New York,10032,United States,"New York, New York, United States",Columbia University Medical Center,"New York, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,New York University,40.71427,-74.00597,New York,New York,10016,United States,"New York, New York, United States",New York University,"New York, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Icahn School of Medicine Mt Sinai,40.71427,-74.00597,New York,New York,10029,United States,"New York, New York, United States",Icahn School of Medicine Mt Sinai,"New York, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Columbia University,40.71427,-74.00597,New York,New York,10032,United States,"New York, New York, United States",Columbia University Medical Center,"New York, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Montefiore Medical Center,40.71427,-74.00597,New York,New York,10461,United States,"New York, New York, United States",Columbia University Medical Center,"New York, New York, United States"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Weill Cornell Medicine,40.71427,-74.00597,New York,New York,10021,United States,"New York, New York, United States",Weill Cornell Medicine,"New York, New York, United States"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Weill Cornell Medicine,40.71427,-74.00597,New York,New York,10021,United States,"New York, New York, United States",Weill Cornell Medicine,"New York, New York, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Columbia University Medical Center,40.71427,-74.00597,New York,New York,10032,United States,"New York, New York, United States",Columbia University Medical Center,"New York, New York, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,Columbia University,40.71427,-74.00597,New York,New York,10032,United States,"New York, New York, United States",Columbia University Medical Center,"New York, New York, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,35.9132,-79.05584,Chapel Hill,North Carolina,27599,United States,"Chapel Hill, North Carolina, United States",Clinical Trial Site,"Chapel Hill, North Carolina, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,30.26715,-97.74306,Austin,Texas,78723,United States,"Austin, Texas, United States",Clinical Trial Site,"Austin, Texas, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,North Austin Maternal Fetal Medicine,30.26715,-97.74306,Austin,Texas,78758,United States,"Austin, Texas, United States",North Austin Maternal Fetal Medicine,"Austin, Texas, United States"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,-27.48034,153.02049,South Brisbane,,,Australia,"South Brisbane, Australia",Clinical Trial Site,"South Brisbane, Queensland, Australia"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Queensland Children?s Hospital,-27.48034,153.02049,South Brisbane,Queensland,4101,Australia,"South Brisbane, Queensland, Australia",Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service,"South Brisbane, Queensland, Australia"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Queensland Children's Hospital,-27.48034,153.02049,South Brisbane,Queensland,4101,Australia,"South Brisbane, Queensland, Australia",Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service,"South Brisbane, Queensland, Australia"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Queensland Children's Hospital,-27.48034,153.02049,South Brisbane,Queensland,4101,Australia,"South Brisbane, Queensland, Australia",Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service,"South Brisbane, Queensland, Australia"
NCT05011851,Neuren Pharmaceuticals Limited,"An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome",2021-08-05,2024-07-16,COMPLETED,Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service,-27.48034,153.02049,South Brisbane,Queensland,4101,Australia,"South Brisbane, Queensland, Australia",Centre for Clinical Trials in Rare Neurodevelopmental Disorders at Children's Health Queensland Hospital and Health Service,"South Brisbane, Queensland, Australia"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,-33.86785,151.20732,Sydney,,,Australia,"Sydney, Australia",Clinical Trial Site,"Sydney, Australia"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,45.50884,-73.58781,Montréal,,,Canada,"Montréal, Canada",Clinical Trial Site,"Montréal, Quebec, Canada"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,The Research Institute of the McGill University Health Centre,45.50884,-73.58781,Montreal,Quebec,H3G 1A4,Canada,"Montreal, Quebec, Canada",The Research Institute of the McGill University Health Centre,"Montréal, Quebec, Canada"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,McGill University Health Centre,45.50884,-73.58781,Montréal,Quebec,,Canada,"Montréal, Quebec, Canada",The Research Institute of the McGill University Health Centre,"Montréal, Quebec, Canada"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,49.24966,-123.11934,Vancouver,,,Canada,"Vancouver, Canada",Clinical Trial Site,"Vancouver, British Columbia, Canada"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,British Columbia Children's Hospital,49.24966,-123.11934,Vancouver,British Columbia,V6H 3V4,Canada,"Vancouver, British Columbia, Canada",British Columbia Children's Hospital,"Vancouver, British Columbia, Canada"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,British Columbia Children's Hospital,49.24966,-123.11934,Vancouver,British Columbia,V6H 3V4,Canada,"Vancouver, British Columbia, Canada",British Columbia Children's Hospital,"Vancouver, British Columbia, Canada"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,BC Children's Hospital,49.24966,-123.11934,Vancouver,British Columbia,,Canada,"Vancouver, British Columbia, Canada",British Columbia Children's Hospital,"Vancouver, British Columbia, Canada"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,53.57532,10.01534,Hamburg,,,Germany,"Hamburg, Germany",Clinical Trial Site,"Hamburg, Germany"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Universitaetsklinikum Hamburg-Eppendorf,53.57532,10.01534,Hamburg,,20246,Germany,"Hamburg, Germany",Universitaetsklinikum Hamburg-Eppendorf,"Hamburg, Germany"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Universitatsklinikum Hamburg-Eppendorf,53.57532,10.01534,Hamburg,,20246,Germany,"Hamburg, Germany",Universitaetsklinikum Hamburg-Eppendorf,"Hamburg, Germany"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,51.33962,12.37129,Leipzig,,,Germany,"Leipzig, Germany",Clinical Trial Site,"Leipzig, Sachsen, Germany"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Universitaetsklinikum Leipzig,51.33962,12.37129,Leipzig,,04103,Germany,"Leipzig, Germany",Universitaetsklinikum Leipzig,"Leipzig, Sachsen, Germany"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Universitatsklinikum Leipzig,51.33962,12.37129,Leipzig,Sachsen,04103,Germany,"Leipzig, Sachsen, Germany",Universitaetsklinikum Leipzig,"Leipzig, Sachsen, Germany"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,48.13743,11.57549,Munich,,,Germany,"Munich, Germany",Clinical Trial Site,"München, Germany"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Dr. Von Haunersches Kinderspital,48.13743,11.57549,München,,80337,Germany,"München, Germany",Dr. Von Haunersches Kinderspital,"München, Germany"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,48.13743,11.57549,Munich,,80804,Germany,"Munich, Germany",Ovid Therapeutics Investigative Site,"München, Germany"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,35.18147,136.90641,Nagoya,,,Japan,"Nagoya, Japan",Clinical Trial Site,"Nagoya, Japan"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,34.69374,135.50218,Osaka,,,Japan,"Osaka, Japan",Clinical Trial Site,"Osaka, Japan"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,43.06667,141.35,Sapporo,,,Japan,"Sapporo, Japan",Clinical Trial Site,"Sapporo, Japan"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,51.9225,4.47917,Rotterdam,,,Netherlands,"Rotterdam, Netherlands",Clinical Trial Site,"Rotterdam, Netherlands"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,51.9225,4.47917,Rotterdam,,3012CN,Netherlands,"Rotterdam, Netherlands",Ovid Therapeutics Investigative Site,"Rotterdam, Netherlands"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Erasmus MC / location Sophia Kinderziekenhuis,51.9225,4.47917,Rotterdam,,3015 GJ,Netherlands,"Rotterdam, Netherlands",Erasmus MC / location Sophia Kinderziekenhuis,"Rotterdam, Netherlands"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,54.35205,18.64637,Gdańsk,,,Poland,"Gdańsk, Poland",Clinical Trial Site,"Gdańsk, Poland"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,51.75,19.46667,Łódź,,,Poland,"Łódź, Poland",Clinical Trial Site,"Łódź, Poland"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,41.38879,2.15899,Barcelona,,,Spain,"Barcelona, Spain",Clinical Trial Site,"Barcelona, Spain"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Dexeus,41.38879,2.15899,Barcelona,,08028,Spain,"Barcelona, Spain",Dexeus,"Barcelona, Spain"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,Hospital Materno Infantil Vall d'Hebron,41.38879,2.15899,Barcelona,,08035,Spain,"Barcelona, Spain",Hospital Materno Infantil Vall d'Hebron,"Barcelona, Spain"
NCT06115109,Puerta de Hierro University Hospital,"Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain",2022-07-26,2025-07-01,RECRUITING,Hospital Parc Tauli. Servicio de Genética molecular,41.38879,2.15899,Barcelona,,08208,Spain,"Barcelona, Spain",Hospital Parc Tauli. Servicio de Genética molecular,"Barcelona, Spain"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,40.4165,-3.70256,Madrid,,,Spain,"Madrid, Spain",Clinical Trial Site,"Madrid, Spain"
NCT02056665,Puerta de Hierro University Hospital,"Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome",2014-02-05,2014-11,COMPLETED,Puerta de Hierro University Hospital,40.4165,-3.70256,Madrid,,28222,Spain,"Madrid, Spain",Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda,"Madrid, Spain"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Hospital Universitario Puerta De Hierro Majadahonda,40.4165,-3.70256,Madrid,,28222,Spain,"Madrid, Spain",Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda,"Madrid, Spain"
NCT06115109,Puerta de Hierro University Hospital,"Observational Study, Prospective Multicentric, From the Natural History of Patients With Angelman Syndrome in Spain",2022-07-26,2025-07-01,RECRUITING,Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda,40.4165,-3.70256,Madrid,,28049,Spain,"Madrid, Spain",Servicio de Farmacología Clínica. Hospital Universitario Puerta de Hierro Majadahonda,"Madrid, Spain"
NCT06617429,Ultragenyx Pharmaceutical Inc,"A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome",2024-09-24,2027-11,RECRUITING,Clinical Trial Site,37.38283,-5.97317,Seville,,,Spain,"Seville, Spain",Clinical Trial Site,"Seville, Spain"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Hospital Universitario Virgen del Rocío,37.38283,-5.97317,Sevilla,,41013,Spain,"Sevilla, Spain",Hospital Universitario Virgen del Rocío,"Seville, Spain"
NCT03650569,FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS,Italian Angelman Syndrome Registry Protocol,2018-06-26,2022-02-16,COMPLETED,FROM (Fondazione per la Ricerca Ospedale Maggiore di Bergamo ),45.69601,9.66721,Bergamo,,24127,Italy,"Bergamo, Italy",FROM (Fondazione per la Ricerca Ospedale Maggiore di Bergamo ),"Bergamo, Italy"
NCT01531582,University of South Florida,The Efficacy of Minocycline in the Treatment of Angelman Syndrome,2012-02-05,2015-09,COMPLETED,Univeristy of South Florida,27.94752,-82.45843,Tampa,Florida,33613,United States,"Tampa, Florida, United States",Univeristy of South Florida,"Tampa, Florida, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,27.94752,-82.45843,Tampa,Florida,,United States,"Tampa, Florida, United States",Ovid Therapeutics Investigative Site,"Tampa, Florida, United States"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,CHU d'Angers,47.46667,-0.55,Angers,,,France,"Angers, France",CHU d'Angers,"Angers, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Jean Minjoz,47.24878,6.01815,Besançon,,,France,"Besançon, France",Hôpital Jean Minjoz,"Besançon, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Gabriel Montpied,45.77966,3.08628,Clermont-Ferrand,,,France,"Clermont-Ferrand, France",Hôpital Gabriel Montpied,"Clermont-Ferrand, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Bicêtre,48.81471,2.36073,Le Kremlin-Bicêtre,,,France,"Le Kremlin-Bicêtre, France",Hôpital Bicêtre,"Le Kremlin-Bicêtre, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Jeanne de Flandre,50.63297,3.05858,Lille,,,France,"Lille, France",Hôpital Jeanne de Flandre,"Lille, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital de la mère et de l'enfant,45.83153,1.25781,Limoges,,,France,"Limoges, France",Hôpital de la mère et de l'enfant,"Limoges, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Femme Mère Enfant,45.74848,4.84669,Lyon,,,France,"Lyon, France",Hôpital Femme Mère Enfant,"Lyon, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital de la Timone,43.29551,5.38958,Marseille,,,France,"Marseille, France",AP-HM - Hopital de la Timone,"Marseille, France"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Hopital la Timone Enfants,43.29551,5.38958,Marseille,,13005,France,"Marseille, France",AP-HM - Hopital de la Timone,"Marseille, France"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,AP-HM - Hopital de la Timone,43.29551,5.38958,Marseille,,13385,France,"Marseille, France",AP-HM - Hopital de la Timone,"Marseille, France"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Hopital de la Timone,43.29551,5.38958,Marseille,,,France,"Marseille, France",AP-HM - Hopital de la Timone,"Marseille, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Brabois,48.68439,6.18496,Nancy,,,France,"Nancy, France",Hôpital Brabois,"Nancy, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital enfant-adolescent,47.21725,-1.55336,Nantes,,,France,"Nantes, France",Hôpital enfant-adolescent,"Nantes, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Armand-Trousseau,48.85341,2.3488,Paris,,,France,"Paris, France",Hôpital Armand-Trousseau,"Paris, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital de la Pitié-Salpêtrière,48.85341,2.3488,Paris,,,France,"Paris, France",Hôpital Robert Debré,"Paris, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital de la Pitié-Salpêtrière,48.85341,2.3488,Paris,,,France,"Paris, France",Hôpital Robert Debré,"Paris, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Necker Enfants Malades,48.85341,2.3488,Paris,,,France,"Paris, France",Hôpital Robert Debré,"Paris, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Robert Debré,48.85341,2.3488,Paris,,,France,"Paris, France",Hôpital Robert Debré,"Paris, France"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Groupe Hospitalier Necker Enfants Malades,48.85341,2.3488,Paris,,75015,France,"Paris, France",Groupe Hospitalier Necker Enfants Malades,"Paris, France"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Necker-Enfants Malades Hospital,48.85341,2.3488,Paris,,75015,France,"Paris, France",Groupe Hospitalier Necker Enfants Malades,"Paris, France"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,AP-HP Hopital Necker-Enfants Malades,48.85341,2.3488,Paris,,75015,France,"Paris, France",Groupe Hospitalier Necker Enfants Malades,"Paris, France"
NCT00773825,Assistance Publique - Hôpitaux de Paris,Assessment of the Risk of Imprinting Defects in Children Born Following Assisted Reproductive Technologies (ART),2008-10-15,2015-06,COMPLETED,Trousseau Hospital,48.85341,2.3488,Paris,,75012,France,"Paris, France",Hôpital Armand-Trousseau,"Paris, France"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,AP-HP Hopital Necker-Enfants Malades,48.85341,2.3488,Paris,,75015,France,"Paris, France",Groupe Hospitalier Necker Enfants Malades,"Paris, France"
NCT06737718,Assistance Publique - Hôpitaux de Paris,Use of Eye Tracking to Study Social Perception Abnormalities in Children with Angelman Syndrome,2024-12-12,2026-01,NOT_YET_RECRUITING,Hôpital Necker-Enfants Malades,48.85341,2.3488,Paris,,75015,France,"Paris, France",Hôpital Robert Debré,"Paris, France"
NCT04768803,"University Hospital, Toulouse","Circulating Levels of Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and / or Overweight, and / or Obesity",2021-02-16,2023-12-15,RECRUITING,Centre N°1 : 40 Centre de Référence PRADORT Pr Tauber - Toulouse Centre N°2 : 22 Centre de Référence PRADORT Pr Poitou Bernert - Paris La Pitié Salpetrière Centre N°3 : 15 Centre de Référence DI de causes rares Dr Heron - Paris La Pitié Salpêtrière Centr,48.85341,2.3488,Paris,,,France,"Paris, France",Centre N°1 : 40 Centre de Référence PRADORT Pr Tauber - Toulouse Centre N°2 : 22 Centre de Référence PRADORT Pr Poitou Bernert - Paris La Pitié Salpetrière Centre N°3 : 15 Centre de Référence DI de causes rares Dr Heron - Paris La Pitié Salpêtrière Centr,"Paris, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Sud,48.11198,-1.67429,Rennes,,,France,"Rennes, France",Hôpital Sud,"Rennes, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Civil,48.58392,7.74553,Strasbourg,,,France,"Strasbourg, France",Hôpital Civil,"Strasbourg,, France"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Strasbourg University Hospital Depatment of Child Psychiatry & Neurology,48.58392,7.74553,"Strasbourg,",,,France,"Strasbourg,, France",Strasbourg University Hospital Depatment of Child Psychiatry & Neurology,"Strasbourg,, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital des Enfants,43.60426,1.44367,Toulouse,,,France,"Toulouse, France",Hôpital des Enfants,"Toulouse, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital des Enfants,43.60426,1.44367,Toulouse,,,France,"Toulouse, France",Hôpital des Enfants,"Toulouse, France"
NCT04768803,"University Hospital, Toulouse","Circulating Levels of Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and / or Overweight, and / or Obesity",2021-02-16,2023-12-15,RECRUITING,Tauber,43.60426,1.44367,Toulouse,,,France,"Toulouse, France",Tauber,"Toulouse, France"
NCT05945576,"Institut National de la Santé Et de la Recherche Médicale, France",National Cohort on Imprinting Disorders and Their Metabolic Consequences,2023-06-26,2032-03-10,RECRUITING,Hôpital Bretonneau,47.38333,0.68333,Tours,,,France,"Tours, France",Hôpital Bretonneau,"Tours, France"
NCT05783791,"University of Wisconsin, Madison",Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome,2023-03-13,2023-07-21,COMPLETED,University of Wisconsin School of Medicine and Public Health,43.07305,-89.40123,Madison,Wisconsin,53705,United States,"Madison, Wisconsin, United States",University of Wisconsin School of Medicine and Public Health,"Madison, Wisconsin, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Carolina Institute for Development DisabilitiesUniversity of North Carolina/School of Medicine,35.91014,-79.07529,Carrboro,North Carolina,27510,United States,"Carrboro, North Carolina, United States",Carolina Institute for Development Disabilities University of North Carolina/School of Medicine,"Carrboro, North Carolina, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,University of North Carolina at Chapel Hill School of Medicine,35.91014,-79.07529,Carrboro,North Carolina,27510,United States,"Carrboro, North Carolina, United States",Carolina Institute for Development Disabilities University of North Carolina/School of Medicine,"Carrboro, North Carolina, United States"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Carolina Institute for Development Disabilities University of North Carolina/School of Medicine,35.91014,-79.07529,Carrboro,North Carolina,27510,United States,"Carrboro, North Carolina, United States",Carolina Institute for Development Disabilities University of North Carolina/School of Medicine,"Carrboro, North Carolina, United States"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,The Carolina Institute for Developmental Disabilities,35.91014,-79.07529,Carrboro,North Carolina,27510,United States,"Carrboro, North Carolina, United States",Carolina Institute for Development Disabilities University of North Carolina/School of Medicine,"Carrboro, North Carolina, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Multicare Institute for Research and Innovation,47.25288,-122.44429,Tacoma,Washington,98405,United States,"Tacoma, Washington, United States",Multicare Institute for Research and Innovation,"Tacoma, Washington, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,47.25288,-122.44429,Tacoma,Washington,85006,United States,"Tacoma, Washington, United States",Ovid Therapeutics Investigative Site,"Tacoma, Washington, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,47.25288,-122.44429,Tacoma,Washington,85006,United States,"Tacoma, Washington, United States",Ovid Therapeutics Investigative Site,"Tacoma, Washington, United States"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Flinders Medical Centre,-35.03333,138.56667,Bedford Park,South Australia,5042,Australia,"Bedford Park, South Australia, Australia",Flinders Medical Centre,"Bedford Park, South Australia, Australia"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,CHRU de Brest,48.3903,-4.48628,Brest,,29609,France,"Brest, France",CHRU de Brest,"Brest, France"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Ospedale Pediatrico Bambino Gesù,41.89193,12.51133,Roma,Lazio,00165,Italy,"Roma, Lazio, Italy",Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione,"Roma, Lazio, Italy"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione,41.89193,12.51133,Roma,Lazio,00165,Italy,"Roma, Lazio, Italy",Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione,"Roma, Lazio, Italy"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,IRCCS Istituto G. Gaslini,44.40478,8.94438,Genova,Liguria,16147,Italy,"Genova, Liguria, Italy",IRCCS Istituto G. Gaslini,"Genova, Liguria, Italy"
NCT05630066,Hoffmann-La Roche,"A Phase IIa Multicenter, Open-Label, 12-Week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype",2022-11-09,2025-09-12,RECRUITING,Corporacio Sanitaria Parc Tauli,41.54329,2.10942,Sabadell,Barcelona,08208,Spain,"Sabadell, Barcelona, Spain",Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,"Sabadell, Barcelona, Spain"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,41.54329,2.10942,Sabadell,,08208,Spain,"Sabadell, Spain",Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,"Sabadell, Barcelona, Spain"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Hospital Universitari Parc Tauli,41.54329,2.10942,Sabadell,Barcelona,,Spain,"Sabadell, Barcelona, Spain",Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,"Sabadell, Barcelona, Spain"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Corporacio Sanitaria Parc Tauli,41.54329,2.10942,Sabadell,Barcelona,08208,Spain,"Sabadell, Barcelona, Spain",Corporacio Sanitaria Parc Tauli - Hospital de Sabadell,"Sabadell, Barcelona, Spain"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Colorado Children's Hospital Research Institute,39.72943,-104.83192,Aurora,Colorado,80045,United States,"Aurora, Colorado, United States",Colorado Children's Hospital Research Institute,"Aurora, Colorado, United States"
NCT03644693,"University of Colorado, Denver",Evaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman Syndrome,2018-08-13,2020-01-15,COMPLETED,Children's Hopsital Colorado,39.72943,-104.83192,Aurora,Colorado,80045,United States,"Aurora, Colorado, United States",Colorado Children's Hospital Research Institute,"Aurora, Colorado, United States"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,"Sydney Children's Hospital, Kids Cancer Centre",-33.91439,151.24895,Randwick,,NSW 2031,Australia,"Randwick, Australia","Sydney Children's Hospital, Kids Cancer Centre","Randwick, New South Wales, Australia"
NCT05011851,Neuren Pharmaceuticals Limited,"An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome",2021-08-05,2024-07-16,COMPLETED,Sydney Children's Hospital,-33.91439,151.24895,Randwick,New South Wales,2031,Australia,"Randwick, New South Wales, Australia","Sydney Children's Hospital, Kids Cancer Centre","Randwick, New South Wales, Australia"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Sheba Medical Center,32.08227,34.81065,Ramat Gan,,5262100,Israel,"Ramat Gan, Israel",Sheba Medical Center,"Ramat Gan, Israel"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,32.08227,34.81065,Ramat Gan,,52621,Israel,"Ramat Gan, Israel",Ovid Therapeutics Investigative Site,"Ramat Gan, Israel"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,The Edmond and Lily Safra Children's Hospital,32.08227,34.81065,Ramat Gan,,,Israel,"Ramat Gan, Israel",The Edmond and Lily Safra Children's Hospital,"Ramat Gan, Israel"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,32.08227,34.81065,Ramat Gan,,52621,Israel,"Ramat Gan, Israel",Ovid Therapeutics Investigative Site,"Ramat Gan, Israel"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,32.08227,34.81065,Ramat Gan,,52621,Israel,"Ramat Gan, Israel",Ovid Therapeutics Investigative Site,"Ramat Gan, Israel"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,Azienda Ospedaliera Universitaria Pisana,43.70853,10.4036,Pisa,,56126,Italy,"Pisa, Italy",Azienda Ospedaliera Universitaria Pisana,"Pisa, Italy"
NCT05127226,"Ionis Pharmaceuticals, Inc.","HALOS: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients With Angelman Syndrome",2021-11-09,2029-03,ACTIVE_NOT_RECRUITING,STRONG Group University of Oxford,51.75222,-1.25596,Oxford,Oxfordshire,OX3 9DU,United Kingdom,"Oxford, Oxfordshire, United Kingdom",STRONG Group University of Oxford,"Oxford, Oxfordshire, United Kingdom"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Oxford University Hospitals NHS Foundation Trust,51.75222,-1.25596,Oxford,,OX3 7LE,United Kingdom,"Oxford, United Kingdom",Oxford University Hospitals NHS Foundation Trust,"Oxford, Oxfordshire, United Kingdom"
NCT05100810,University of Oxford,"A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in the United Kingdom: Natural History - Foundation for Angelman Syndrome Therapeutics (FAST) United Kingdom (UK)",2021-08-13,2024-12-31,RECRUITING,University of Oxford,51.75222,-1.25596,Oxford,Oxon,OX3 9DU,United Kingdom,"Oxford, Oxon, United Kingdom",STRONG Group University of Oxford,"Oxford, Oxfordshire, United Kingdom"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Oxford University Hospitals NHS Foundation Trust,51.75222,-1.25596,Oxford,,OX3 7LE,United Kingdom,"Oxford, United Kingdom",Oxford University Hospitals NHS Foundation Trust,"Oxford, Oxfordshire, United Kingdom"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,33.44838,-112.07404,Phoenix,Arizona,85006,United States,"Phoenix, Arizona, United States",Ovid Therapeutics Investigative Site,"Phoenix, Arizona, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Southwest Autism Research and Resource Center (SARRC),33.44838,-112.07404,Phoenix,Arizona,85006,United States,"Phoenix, Arizona, United States",Southwest Autism Research and Resource Center (SARRC),"Phoenix, Arizona, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,33.44838,-112.07404,Phoenix,Arizona,85006,United States,"Phoenix, Arizona, United States",Ovid Therapeutics Investigative Site,"Phoenix, Arizona, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,33.44838,-112.07404,Phoenix,Arizona,85006,United States,"Phoenix, Arizona, United States",Ovid Therapeutics Investigative Site,"Phoenix, Arizona, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,42.44732,-71.2245,Lexington,Massachusetts,02421,United States,"Lexington, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Lexington, Massachusetts, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,42.44732,-71.2245,Lexington,Massachusetts,02421,United States,"Lexington, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Lexington, Massachusetts, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,42.44732,-71.2245,Lexington,Massachusetts,02421,United States,"Lexington, Massachusetts, United States",Ovid Therapeutics Investigative Site,"Lexington, Massachusetts, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,39.12713,-84.51435,Cincinnati,Ohio,45229,United States,"Cincinnati, Ohio, United States",Ovid Therapeutics Investigative Site,"Cincinnati, Ohio, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,39.12713,-84.51435,Cincinnati,Ohio,45229,United States,"Cincinnati, Ohio, United States",Ovid Therapeutics Investigative Site,"Cincinnati, Ohio, United States"
NCT00296764,Boston Children's Hospital,Angelman Syndrome Natural History Study,2006-02-24,2014-08,COMPLETED,Cincinnati Children's Hospital and Medical Center,39.12713,-84.51435,Cincinnati,Ohio,45229,United States,"Cincinnati, Ohio, United States",Cincinnati Children's Hospital and Medical Center,"Cincinnati, Ohio, United States"
NCT01281475,Boston Children's Hospital,A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome,2011-01-20,2015-07,COMPLETED,Cincinnati Children's Hospital,39.12713,-84.51435,Cincinnati,Ohio,45229,United States,"Cincinnati, Ohio, United States",Cincinnati Children's Hospital and Medical Center,"Cincinnati, Ohio, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,39.12713,-84.51435,Cincinnati,Ohio,45229,United States,"Cincinnati, Ohio, United States",Ovid Therapeutics Investigative Site,"Cincinnati, Ohio, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,39.91678,-75.38769,Media,Pennsylvania,19063,United States,"Media, Pennsylvania, United States",Ovid Therapeutics Investigative Site,"Media, Pennsylvania, United States"
NCT03882918,Ovid Therapeutics Inc.,"An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome",2019-03-18,2021-06-30,TERMINATED,Ovid Therapeutics Investigative Site,39.91678,-75.38769,Media,Pennsylvania,19063,United States,"Media, Pennsylvania, United States",Ovid Therapeutics Investigative Site,"Media, Pennsylvania, United States"
NCT02996305,Ovid Therapeutics Inc.,"A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol",2016-12-02,2018-08-06,COMPLETED,Ovid Therapeutics Investigative Site,39.91678,-75.38769,Media,Pennsylvania,19063,United States,"Media, Pennsylvania, United States",Ovid Therapeutics Investigative Site,"Media, Pennsylvania, United States"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,-27.46794,153.02809,Brisbane,Queensland,4101,Australia,"Brisbane, Queensland, Australia",Ovid Therapeutics Investigative Site,"Brisbane, Queensland, Australia"
NCT05293184,"Foundation for Angelman Syndrome Therapeutics, Australia",The Global Angelman Syndrome Registry,2017-06-27,2099-12-31,RECRUITING,Queensland University of Technology,-27.46794,153.02809,Brisbane,Queensland,4000,Australia,"Brisbane, Queensland, Australia",Queensland University of Technology,"Brisbane, Queensland, Australia"
NCT04106557,Ovid Therapeutics Inc.,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of OV101 in Pediatric Individuals With Angelman Syndrome",2019-09-25,2020-11-02,COMPLETED,Ovid Therapeutics Investigative Site,-37.75,145.06667,Heidelberg,Victoria,3084,Australia,"Heidelberg, Victoria, Australia",Ovid Therapeutics Investigative Site,"Heidelberg, Victoria, Australia"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Austin Health,-37.75,145.06667,Heidelberg,Victoria,3084,Australia,"Heidelberg, Victoria, Australia",Austin Health,"Heidelberg, Victoria, Australia"
NCT05011851,Neuren Pharmaceuticals Limited,"An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome",2021-08-05,2024-07-16,COMPLETED,Austin Health,-37.75,145.06667,Heidelberg,Victoria,3084,Australia,"Heidelberg, Victoria, Australia",Austin Health,"Heidelberg, Victoria, Australia"
NCT06353620,IRCCS Eugenio Medea,Structural-functional Connectome With High-density Electroencephalography in Drug-resistant Epilepsies and Rare Neurodevelopmental Syndromes With Epilepsy,2024-03-20,2027-02-28,RECRUITING,IRCCS E.Medea,45.88805,12.30201,Conegliano,Treviso,31015,Italy,"Conegliano, Treviso, Italy","I.R.C.C.S. ""E.Medea""","Conegliano, Treviso, Italy"
NCT06337383,IRCCS Eugenio Medea,"Study of the Prevalence of Autistic Traits in Angelman Syndrome, the Correlation With Cognitive Level, Epilepsy, With Socio-communication Skills and Parenting Styles",2024-03-21,2024-06,RECRUITING,"I.R.C.C.S. ""E.Medea""",45.88805,12.30201,Conegliano,Treviso,31015,Italy,"Conegliano, Treviso, Italy","I.R.C.C.S. ""E.Medea""","Conegliano, Treviso, Italy"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,"Crystal BioMedical Research, LLC",25.90871,-80.30866,Miami Lakes,Florida,33014,United States,"Miami Lakes, Florida, United States","Crystal BioMedical Research, LLC","Miami Lakes, Florida, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Lake Mary Pediatrics,28.94888,-81.29867,Orange City,Florida,32763,United States,"Orange City, Florida, United States",Lake Mary Pediatrics,"Orange City, Florida, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Mate Lazlo,26.71534,-80.05337,West Palm Beach,Florida,33408,United States,"West Palm Beach, Florida, United States",Mate Lazlo,"West Palm Beach, Florida, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,"Attalla Consultants LLC, dba Institue for Behabiovral medicine",33.88399,-84.51438,Smyrna,Georgia,30080-6315,United States,"Smyrna, Georgia, United States","Attalla Consultants LLC, dba Institue for Behabiovral medicine","Smyrna, Georgia, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,AMR Baber research INC,41.78586,-88.14729,Naperville,Illinois,60563,United States,"Naperville, Illinois, United States",AMR Baber research INC,"Naperville, Illinois, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Kennedy Krieger Institute,39.29038,-76.61219,Baltimore,Maryland,21205,United States,"Baltimore, Maryland, United States",Kennedy Krieger Institute,"Baltimore, Maryland, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Child Neurology Specialists/ CRCN,36.0397,-114.98194,Henderson,Nevada,89052,United States,"Henderson, Nevada, United States",Child Neurology Specialists/ CRCN,"Henderson, Nevada, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,"Clinical research center of New Jersey, LLC",40.48122,-74.48321,Voorhees,New Jersey,08043,United States,"Voorhees, New Jersey, United States","Clinical research center of New Jersey, LLC","Voorhees, New Jersey, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Geinsinger Clinic,40.96342,-76.61273,Danville,Pennsylvania,17822,United States,"Danville, Pennsylvania, United States",Geinsinger Clinic,"Danville, Pennsylvania, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,The children's hospital of Philadelphia,39.95233,-75.16379,Philadelphia,Pennsylvania,19104-4399,United States,"Philadelphia, Pennsylvania, United States",The children's hospital of Philadelphia,"Philadelphia, Pennsylvania, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,The Children's Hospital of Philadelphia,39.95233,-75.16379,Philadelphia,Pennsylvania,19104,United States,"Philadelphia, Pennsylvania, United States",The children's hospital of Philadelphia,"Philadelphia, Pennsylvania, United States"
NCT02109770,"Natera, Inc.",Development of Non-invasive Prenatal Test for Microdeletion/Duplication and Other Genetic Syndromes Based on Fetal DNA Isolated From Maternal Blood,2014-04-08,2019-08,COMPLETED,Children's Hospital Of Philadelphia,39.95233,-75.16379,Philadelphia,Pennsylvania,19104,United States,"Philadelphia, Pennsylvania, United States",The children's hospital of Philadelphia,"Philadelphia, Pennsylvania, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,INSITE Clinical Research,32.58986,-96.85695,DeSoto,Texas,75115,United States,"DeSoto, Texas, United States",INSITE Clinical Research,"DeSoto, Texas, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Sleep Therapy & Research Center,29.42412,-98.49363,San Antonio,Texas,78229,United States,"San Antonio, Texas, United States",Sleep Therapy & Research Center,"San Antonio, Texas, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,"Road Runner Research, Ltd",29.42412,-98.49363,San Antonio,Texas,78258,United States,"San Antonio, Texas, United States","Road Runner Research, Ltd","San Antonio, Texas, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Ericksen Research & Development,41.13967,-112.0505,Clinton,Utah,32763,United States,"Clinton, Utah, United States",Ericksen Research & Development,"Clinton, Utah, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Pacific institute of medical science,47.76232,-122.2054,Bothell,Washington,98011,United States,"Bothell, Washington, United States",Pacific institute of medical science,"Bothell, Washington, United States"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Helsinki Sleep Clinic Vitalmed OY,60.16952,24.93545,Helsinki,,,Finland,"Helsinki, Finland",Helsinki Sleep Clinic Vitalmed OY,"Helsinki, Finland"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Hospital Raymond Poincare,48.84226,2.18232,Garches,,,France,"Garches, France",Hospital Raymond Poincare,"Garches, France"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Yulius Mental Health Organization,51.81,4.67361,Dordrecht,,,Netherlands,"Dordrecht, Netherlands",Yulius Mental Health Organization,"Dordrecht, Netherlands"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Hospital Gelderse Vallei,52.03333,5.65833,Ede,,,Netherlands,"Ede, Netherlands",Hospital Gelderse Vallei,"Ede, Netherlands"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Birmingham Childrens Hospital NHS FOUNDATION TRUST,52.48142,-1.89983,Birmingham,,,United Kingdom,"Birmingham, United Kingdom",Birmingham Childrens Hospital NHS FOUNDATION TRUST,"Birmingham, United Kingdom"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Blackpool Victoria Teaching Hospitals NHS Foundation Trust,53.81667,-3.05,Blackpool,,,United Kingdom,"Blackpool, United Kingdom",Blackpool Victoria Teaching Hospitals NHS Foundation Trust,"Blackpool, United Kingdom"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital,51.50853,-0.12574,London,,,United Kingdom,"London, United Kingdom",Guy's & St. Thomas's NHS Foundation Trust of St Thomas's Hospital,"London, United Kingdom"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,St. George University Hospital,51.50853,-0.12574,London,,SW17 0QT,United Kingdom,"London, United Kingdom",St. George University Hospital,"London, United Kingdom"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Great Ormond Street Hospital for Children,51.50853,-0.12574,London,,WC1N 3JH,United Kingdom,"London, United Kingdom",Great Ormond Street Hospital for Children,"London, United Kingdom"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Great Ormond Street Hospital for Children,51.50853,-0.12574,London,,WC1N 3JH,United Kingdom,"London, United Kingdom",Great Ormond Street Hospital for Children,"London, United Kingdom"
NCT01906866,Neurim Pharmaceuticals Ltd.,"A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities",2013-07-11,2018-03-27,COMPLETED,University Hospital Southampton NHS Foundation Trust,50.90395,-1.40428,Southampton,,,United Kingdom,"Southampton, United Kingdom",University Hospital Southampton NHS Foundation Trust,"Southampton, United Kingdom"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Cooper University Hospital,39.92595,-75.11962,Camden,New Jersey,08103,United States,"Camden, New Jersey, United States",Cooper University Hospital,"Camden, New Jersey, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Virtua,39.934,-74.891,Mount Laurel,New Jersey,08054,United States,"Mount Laurel, New Jersey, United States",Virtua,"Mount Laurel, New Jersey, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,St. Peter's University,40.48622,-74.45182,New Brunswick,New Jersey,08901,United States,"New Brunswick, New Jersey, United States",Saint Peter's University Hospital,"New Brunswick, New Jersey, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,Saint Peter's University Hospital,40.48622,-74.45182,New Brunswick,New Jersey,08901,United States,"New Brunswick, New Jersey, United States",Saint Peter's University Hospital,"New Brunswick, New Jersey, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Complete Women's Healthcare,40.72677,-73.6343,Garden City,New York,11530,United States,"Garden City, New York, United States",Complete Women's Healthcare,"Garden City, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,North Shore University Hospital,40.79788,-73.69957,Manhasset,New York,11030,United States,"Manhasset, New York, United States",North Shore University Hospital,"Manhasset, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Madonna Perinatal,40.74927,-73.64068,Mineola,New York,11501,United States,"Mineola, New York, United States",Madonna Perinatal,"Mineola, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Long Island Jewish Medical Center,40.7351,-73.68791,New Hyde Park,New York,11040,United States,"New Hyde Park, New York, United States",Long Island Jewish Medical Center,"New Hyde Park, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Suffolk OB,40.94649,-73.06927,Port Jefferson,New York,11777,United States,"Port Jefferson, New York, United States",Suffolk OB,"Port Jefferson, New York, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Zeid Women's Health Center,32.5007,-94.74049,Longview,Texas,75601,United States,"Longview, Texas, United States",Zeid Women's Health Center,"Longview, Texas, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,University of Utah,40.76078,-111.89105,Salt Lake City,Utah,84132,United States,"Salt Lake City, Utah, United States",University of Utah,"Salt Lake City, Utah, United States"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Royal Prince Alfred,-33.88965,151.17642,Camperdown,New South Wales,2050,Australia,"Camperdown, New South Wales, Australia",Royal Prince Alfred,"Camperdown, New South Wales, Australia"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Royal College Surgeons in Ireland,53.33306,-6.24889,Dublin,,1,Ireland,"Dublin, Ireland",Royal College Surgeons in Ireland,"Dublin, Ireland"
NCT02381457,"Natera, Inc.",SNP-based Microdeletion and Aneuploidy RegisTry,2015-03-02,2020-06,COMPLETED,Sahlgrenska University Hospital,57.70716,11.96679,Gothenburg,,SE-416 85,Sweden,"Gothenburg, Sweden",Sahlgrenska University Hospital,"Gothenburg, Sweden"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,The Royal Children's Hospital,-37.814,144.96332,Melbourne,Victoria,3052,Australia,"Melbourne, Victoria, Australia",The Royal Children's Hospital,"Melbourne, Victoria, Australia"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,MAGIC Clinic Ltd,51.05011,-114.08529,Calgary,Alberta,T2E 7Z4,Canada,"Calgary, Alberta, Canada",MAGIC Clinic Ltd,"Calgary, Alberta, Canada"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,MAGIC Clinic Ltd,51.05011,-114.08529,Calgary,Alberta,T2E 7Z4,Canada,"Calgary, Alberta, Canada",MAGIC Clinic Ltd,"Calgary, Alberta, Canada"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Alberta Children's Hospital,51.05011,-114.08529,Calgary,Alberta,,Canada,"Calgary, Alberta, Canada",Alberta Children's Hospital,"Calgary, Alberta, Canada"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Childrens Hospital London Health Sciences Centre,42.98339,-81.23304,London,Ontario,N6A 5W9,Canada,"London, Ontario, Canada",Childrens Hospital London Health Sciences Centre,"London, Ontario, Canada"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Children's Hospital of Western Ontario,42.98339,-81.23304,London,Ontario,,Canada,"London, Ontario, Canada",Children's Hospital of Western Ontario,"London, Ontario, Canada"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Childrens Hospital of Eastern Ontario,45.41117,-75.69812,Ottawa,Ontario,K1H 8L1,Canada,"Ottawa, Ontario, Canada",Children's Hospital of Eastern Ontario,"Ottawa, Ontario, Canada"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Children's Hospital of Eastern Ontario,45.41117,-75.69812,Ottawa,Ontario,K1H 8L1,Canada,"Ottawa, Ontario, Canada",Children's Hospital of Eastern Ontario,"Ottawa, Ontario, Canada"
NCT04507997,Boston Children's Hospital,Angelman Syndrome Natural History Study,2020-08-05,2025-08,RECRUITING,Children's Hospital of Eastern Ontario,45.41117,-75.69812,Ottawa,Ontario,K1H 8L1,Canada,"Ottawa, Ontario, Canada",Children's Hospital of Eastern Ontario,"Ottawa, Ontario, Canada"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Sheba Medical Center,32.04195,34.85623,Tel HaShomer,,5265601,Israel,"Tel HaShomer, Israel",Sheba Medical Center,"Tel HaShomer, Israel"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,Hospital Universitario Puerta de Hierro,40.47353,-3.87182,Majadahonda,Madrid,28222,Spain,"Majadahonda, Madrid, Spain",Hospital Universitario Puerta de Hierro,"Majadahonda, Madrid, Spain"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Hospital Universitario Puerta de Hierro,40.47353,-3.87182,Majadahonda,Madrid,28222,Spain,"Majadahonda, Madrid, Spain",Hospital Universitario Puerta de Hierro,"Majadahonda, Madrid, Spain"
NCT06415344,Ultragenyx Pharmaceutical Inc,A Long-term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome,2024-05-10,2029-02,ENROLLING_BY_INVITATION,University of Cambridge,52.2,0.11667,Cambridge,,CB2 0QQ,United Kingdom,"Cambridge, United Kingdom",Cambridge University Hospitals,"Cambridge, United Kingdom"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Cambridge University Hospitals,52.2,0.11667,Cambridge,,,United Kingdom,"Cambridge, United Kingdom",Cambridge University Hospitals,"Cambridge, United Kingdom"
NCT04155944,National Cheng-Kung University Hospital,Dr. Pao-Lin Kuo (Department of Obstetrics and Gynecology),2019-10-28,2014-12,COMPLETED,National Cheng-Kung University Hospital,22.99083,120.21333,Tainan,,70428,Taiwan,"Tainan, Taiwan",National Cheng-Kung University Hospital,"Tainan, Taiwan"
NCT03358823,Fudan University,Study on the Brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data,2017-11-25,2019-05-20,COMPLETED,Children's Hospital of Fudan University,31.22222,121.45806,Shanghai,Shanghai,200232,China,"Shanghai, Shanghai, China",Children's Hospital of Fudan University,"Shanghai, Shanghai, China"
NCT03655223,RTI International,Early Check: A Collaborative Innovation to Facilitate Pre-Symptomatic Clinical Trials in Newborns,2018-08-16,2025-12-31,ENROLLING_BY_INVITATION,RTI International,35.90567,-78.90497,Research Triangle Park,North Carolina,27709,United States,"Research Triangle Park, North Carolina, United States",RTI International,"Research Triangle Park, North Carolina, United States"
NCT03836300,RTI International,Piloting an Early Intervention Program for Infants With Rare Neurogenetic Disorders,2019-02-07,2025-06-30,ENROLLING_BY_INVITATION,RTI International,35.90567,-78.90497,Research Triangle Park,North Carolina,27709,United States,"Research Triangle Park, North Carolina, United States",RTI International,"Research Triangle Park, North Carolina, United States"
NCT06229769,Centre Hospitalier Universitaire de Liege,"A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in CHR Citadelle Liège : NatHis-Angelman",2023-11-02,2028-01,RECRUITING,CHR Citadelle Liège,50.63373,5.56749,Liège,,4000,Belgium,"Liège, Belgium",CHR Citadelle Liège,"Liège, Belgium"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,The Royal Children's Hospital,-37.78333,144.95,Parkville,Victoria,3052,Australia,"Parkville, Victoria, Australia",The Royal Children's Hospital,"Parkville, Victoria, Australia"
NCT04259281,Ultragenyx Pharmaceutical Inc,"A Phase 1/2 Open-label, Multiple-dose, Dose-escalating Clinical Trial of the Safety and Tolerability of GTX-102 in Pediatric Patients With Angelman Syndrome (AS)",2020-01-31,2024-12,ACTIVE_NOT_RECRUITING,Hospital Sant Joan de Deu,41.37732,2.08809,Esplugues De Llobregat,Barcelona,,Spain,"Esplugues De Llobregat, Barcelona, Spain",Hospital Sant Joan de Deu,"Esplugues De Llobregat, Barcelona, Spain"
NCT01903681,Neurim Pharmaceuticals Ltd.,"Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances",2013-07-16,2014-04,COMPLETED,Centre for Human Drug Research,52.15833,4.49306,Leiden,,2333,Netherlands,"Leiden, Netherlands",Centre for Human Drug Research,"Leiden, Netherlands"
NCT04428281,Hoffmann-La Roche,"An Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7248824 in Participants With Angelman Syndrome",2020-06-09,2025-07-31,ACTIVE_NOT_RECRUITING,Mayo Clinic - Rochester,44.02163,-92.4699,Rochester,Minnesota,55905,United States,"Rochester, Minnesota, United States",Mayo Clinic - Rochester,"Rochester, Minnesota, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,"Natera, Inc.",37.50716,-122.26052,San Carlos,California,94070,United States,"San Carlos, California, United States","Natera, Inc.","San Carlos, California, United States"
NCT02109770,"Natera, Inc.",Development of Non-invasive Prenatal Test for Microdeletion/Duplication and Other Genetic Syndromes Based on Fetal DNA Isolated From Maternal Blood,2014-04-08,2019-08,COMPLETED,Natera,37.50716,-122.26052,San Carlos,California,94070,United States,"San Carlos, California, United States","Natera, Inc.","San Carlos, California, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,MFM Group of Southern CA,34.09611,-118.10583,San Gabriel,California,91776,United States,"San Gabriel, California, United States",MFM Group of Southern CA,"San Gabriel, California, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,Washington Women's Wellness Center,38.89511,-77.03637,Washington,District of Columbia,20010,United States,"Washington, District of Columbia, United States",Washington Women's Wellness Center,"Washington, District of Columbia, United States"
NCT01852708,"Natera, Inc.",Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood,2013-05-06,2020-10,COMPLETED,GenePhile Biosciences,25.04776,121.53185,Taipei,,10050,Taiwan,"Taipei, Taiwan",GenePhile Biosciences,"Taipei, Taiwan"
NCT04103333,Biogen,A Study to Explore Cerebrospinal Fluid and Blood Biomarkers in Participants With Angelman Syndrome,2019-09-24,2022-01-02,COMPLETED,University of North Carolina Hospital,36.1318,-79.41252,Carolina,North Carolina,27514,United States,"Carolina, North Carolina, United States",University of North Carolina Hospital,"Carolina, North Carolina, United States"
NCT03720028,Universitaire Ziekenhuizen KU Leuven,Parent-child Interaction and Communication in Families Who Have a Child With Rett Syndrome or Angelman Syndrome,2018-10-23,2020-07-01,COMPLETED,Katholieke Universiteit Leuven,50.87959,4.70093,Leuven,Vlaams-Brabant,3000,Belgium,"Leuven, Vlaams-Brabant, Belgium",Katholieke Universiteit Leuven,"Leuven, Vlaams-Brabant, Belgium"
NCT05637697,"The Emmes Company, LLC",Angelman Syndrome Video Assessment (ASVA) Source Material Study,2022-08-11,2023-08-01,COMPLETED,Casimir,41.99455,-70.72448,Kingston,Massachusetts,02364,United States,"Kingston, Massachusetts, United States",Casimir,"Kingston, Massachusetts, United States"
